# **Earnings Results** Quarter Ended June 30, 2022



## **Forward-Looking Statements and Non-GAAP Financial Measures**

#### Forward-Looking Statements

This presentation may contain forward-looking statements. Information on factors that could cause results to differ materially from those projected in this presentation is available in our Form 10-K for the year ended December 31, 2021 as may be modified by subsequent Forms 10-Q. These documents are available in the Investor Relations section of our website, <u>https://investors.primerica.com</u>. The forward-looking statements speak as of the date on which they were made and the Company does not undertake any obligation to update or correct any forward-looking statements.

#### **Non-GAAP Financial Measures**

This presentation also contains non-GAAP financial measures. A reconciliation of those measures to GAAP financial measures is included in our Financial Supplement, which is posted in the Investor Relations section of our website, https://investors.primerica.com.



# **Financial Highlights**

- Diluted adjusted operating EPS of \$2.86
  - Term Life segment continued to grow, providing a dependable source of capital
  - Investment & Savings Products segment pressured by equity market correction
  - Senior Health segment results reflected seasonally less productive second quarter and our efforts to manage growth
  - Temporary elevated operating expenses
- Capital deployment during the second quarter of 2022
  - Repurchased \$128 million of common stock
  - Paid \$21 million in stockholder dividends
  - Company expects to complete its share repurchase program in the third quarter

#### **GAAP** Financial Results

(\$ in millions, except per-share amounts)	Q2 2022	Q2 2021	% Change
Revenues	\$668.7	\$654.7	2%
Net income attributable to Primerica, Inc.	\$107.9	\$128.2	(16%)
Stockholders' equity (1)	\$1,775.5	\$2,018.8	(12%)
Diluted EPS <sup>(2)</sup>	\$2.79	\$3.22	(13%)
Book value per share <sup>(1) (3)</sup>	\$47.01	\$51.18	(8%)
ROE	23.3%	26.3%	

#### **Adjusted Operating Financial Results**

(\$ in millions, except per-share amounts)	Q2 2022	Q2 2021	% Change
Adjusted operating revenues	\$671.8	\$654.2	3%
Adjusted net operating income	\$110.7	\$129.4	(14%)
Adjusted stockholders' equity (1)	\$1,951.3	\$1,921.8	2%
Diluted adjusted operating EPS <sup>(2)</sup>	\$2.86	\$3.25	(12%)
Adjusted book value per share <sup>(1) (3)</sup>	\$51.66	\$48.72	6%
Adjusted operating ROAE	22.5%	27.8%	

For a reconciliation of GAAP to non-GAAP financial measures refer to pages 4, 7 and 8 of the Financial Supplement

- Reflects the Company's permanent stockholders' equity and does not include temporary stockholders' equity
- (2) 38.5 million weighted-average common shares outstanding for Q2 2022

(3) 37.8 million common shares outstanding as of June 30, 2022



3

## **Production Highlights**

#### Term Life Insurance

- Issued 77,000 new life insurance policies
   Expect second half 2022 sales to increase 5%
- Productivity at 0.20 policies per life insurance licensed representative per month
  - Within historical range of 0.18 to 0.22
- Life insurance face amount in force increased 3% year-over-year
  - Average face amount per policy continued to grow

#### Production

Life	(\$ in billions)	Q2 2022	Q2 2021	% Change
	Issued life insurance policies	76,946	90,071	(15%)
	Face amount issued	\$27.7	\$30.0	(8%)
Term	Life insurance face amount in force <sup>(1)</sup>	\$914.4	\$886.5	3%
	Productivity	0.20	0.23	
	<sup>(1)</sup> At period end			

## Issued Term Life Policies

(in thousands)





## **Production Highlights**

#### **Investment and Savings Products**

- Results impacted by market volatility
  - Sales of \$2.7 billion declined 11% yearover-year
  - Net client inflows of \$900 million versus
     \$1.2 billion in prior year period
  - Average client asset values of \$88 billion declined 2% year-over-year
  - Expect Q3 sales to decline mid-20% range year-over-year
- Clients remain focused on long-term goals
  - 70% of client assets are invested in retirement accounts
  - 20% of mutual funds sales are funded through automatic monthly payments

#### Production

	(\$ in billions)	Q2 2022	Q2 2021	% Change
٩	Total product sales	\$2.69	\$3.04	(12%)
ISP	Client asset values, end of period	\$82.29	\$91.74	(10%)
	Average client asset values	\$87.99	\$89.38	(2%)

#### **ISP Production**

(\$ in billions)



# **Senior Health Business**

- Remain committed to drive turn-around at e-TeleQuote
  - Manage sales volume
  - Focus on per-unit economics to reach sustainable ratio of revenues to acquisition costs
- Referrals from Primerica representatives to e-TeleQuote licensed agents have outperformed traditional leads
- Acquired the remaining 20% of Primerica Health, owner of e-TeleQuote, in July
  - Contractually defined formulaic price indicated zero value for the remaining stake. No cash was
    requited to obtain the remaining shares.



## **Distribution Highlights**

- Strong recruiting versus historical average, reflecting attractiveness of building a Primerica business
  - Recruiting incentives heavily used in prior year due to COVID pandemic
- New life licensed reps increased 14%, reflecting revamped licensing process and new tools
- Life insurance licensed sales force grew for third consecutive quarter

#### Sales Force

_		Q2 2022	Q2 2021	% Change
tion	Recruits	70,215	89,285	(21%)
ribu	New life licensed representatives	11,529	10,112	14%
Distri	Life insurance licensed sales force <sup>(1) (2)</sup>	132,149	132,041	>0%
	Securities licensed sales force	26,126	25,856	1%

#### Life Insurance Licensed Sales Force<sup>(1)</sup> (in thousands)



(1) at period end

(2) Q2 2021 included approximately 2,400 individuals that the Company estimated would not pursue the necessary steps to obtain a permanent license or renew a license with an extended renewal date

(3) YE 2020 included approximately 4,200 individuals that the Company estimated would not pursue the necessary steps to obtain a permanent license or renew a license with an extended renewal date
PRIMERICA

## **Operating Results** Term Life Segment

## Q2 2022 versus Q2 2021

- Operating revenues increased 7% while operating income before income taxes increased 3%
  - Adjusted direct premium grew 8%
  - Persistency and claims experience normalized
  - Insurance expenses were temporarily elevated
- Claims experience:
  - COVID claims, net of reinsurance, of \$2 million
  - Non-COVID claims, below historical trends at \$5 million favorable
- Term Life operating margin strong at 21%
- Third quarter 2022 outlook:
  - ADP growth of 7%
  - Benefits and claim ratio in the low 59% range
  - DAC ratio in line with historical third quarter trends

(\$ in millions)	Q2 2022	Q2 2021	% Change
Direct premiums	\$803.5	\$774.5	4%
Premium ceded to IPO coinsurers <sup>(1)</sup>	(\$231.8)	(\$246.9)	6%
Adjusted direct premiums (ADP) <sup>(2)</sup>	\$571.6	\$527.6	8%
Operating revenues	\$410.7	\$383.5	7%
Operating income before income taxes	\$119.9	\$116.8	3%

Key Ratios	Q2 2022	Q2 2021
Benefits and claims, net <sup>(3)</sup>	58.5%	62.1%
DAC amortization & insurance commissions	14.6%	10.8%
Insurance expenses, net <sup>(4)</sup>	8.0%	6.6%
Term life income before income taxes	21.0%	22.1%

(1) Premiums ceded to IPO coinsurers under the IPO coinsurance transactions excluding any reimbursements from IPO coinsurers on previously existing reinsurance agreements

- (2) Direct premiums net of premiums ceded to IPO coinsurers
- (3) Benefits and claims net of other ceded premiums, which are largely YRT
- (4) Insurance expenses net of other, net revenues



## **Operating Results**

#### **Investment & Savings Products Segment**

## Q2 2022 versus Q2 2021

- Investment and Savings Products segment results are highly correlated to equity markets
- Sales-based revenues of \$89 million were in line with revenue-generating sales
- Asset-based revenues of \$108 million were flat year-over-year
  - Canadian segregated fund DAC amortization increased \$3.7 million year-over-year, reflecting market volatility
- Third quarter 2022 outlook:
  - Asset-based net revenues decline ~ \$3 million at today's market levels
  - Sales-based net revenues decline ~ \$10 million

(\$ in millions, except as noted)	Q2 2022	Q2 2021	% Change
Sales-based revenues	\$88.7	\$104.7	(15%)
Asset-based revenues	\$108.1	\$108.5	(<1%)
Account-based revenues	\$22.6	\$21.8	3%
Other, net	\$3.0	\$3.0	2%
Total operating revenues	\$222.4	\$238.0	(7%)
Benefits and expenses	\$163.4	\$166.9	(2%)
Operating income before income taxes	\$59.0	\$71.2	(17%)
Sales-based net revenue as % of revenue- generating sales <sup>(1)</sup>	1.21%	1.23%	V j
Asset-based net revenue as % of average asset values $^{\rm (2)}$	0.046%	0.050%	
Account-based net revenue per average fee generating position <sup>(3) (4)</sup>	\$4.08	\$4.08	

(1) Commission and fee revenue less commissions paid to the sales force based on product sales activity

- (2) Commission and fee revenue less administration and advisory fees paid to third-party providers and commissions paid to the sales force earned based on product account values including amortization of deferred acquisition costs for segregated funds
- (3) Fee revenue less recordkeeping fees paid to third-party providers based on fee-generating positions and certain direct general expenses
- (4) In whole dollars



# **Senior Health Business**

- \$5.4 million negative tail adjustment reflects refinements for policies sold during most recent AEP and OEP
- Deliberate efforts to improve LTVs and reduce costs
  - New agent compensation model
  - Use of data science to identify and route leads
- Outlook:
  - Full year pre-tax operating loss of ~\$35 million
  - <\$10 million needed from Primerica for full year funding

(\$ in thousands)	Q2 2022
Commissions and fees	\$9,343
Operating revenues	\$11,814
Contract acquisition costs	\$19,384
Other operating expenses	\$8,514
Non-controlling interest before taxes	(\$3,129)
Operating income before income taxes	(\$12,955)

#### Production

ے		Q2 2022
Health	Approved policies <sup>(1)</sup>	17,925
	LTV per approved policy	\$820
enior	CAC per approved policy	\$1,081
Sel	LTV/CAC multiple	0.8 x

(1) Senior Health approved policies represent an estimate of submitted policies approved by health insurance carriers during the indicated period. Not all approved policies will go in force.



# **Insurance & Operating Expense Highlights**

- Operating expenses of \$139 million were \$23% higher than prior year:
  - \$8.5 million from senior health segment
  - \$8.0 million from in-person sales force leadership events/travel
  - Remainder from growth in the business, employee compensation and technology

## • Outlook:

- Q3 2022 growth of 8%
- Q4 2022 growth of 6%

### INSURANCE & OPERATING EXPENSES

(\$ in millions)	Cons *	Life	ISP	Corp
Q2 2021 Insurance & Other Operating Expenses *	113.2	47.3	37.2	28.7
Salesforce leadership events & travel expenses	8.0	6.4	1.2	0.4
Employee-related expenses	2.2	1.1	0.2	1.0
Growth-related expenses	1.7	1.2	0.3	0.2
Other growth in business expenses	5.2	2.4	1.4	1.4
Q2 2022 Insurance & Other Operating Expenses *	130.2	58.3	40.2	31.7
Q2 2022 Senior Health expenses	8.5			
Q2 2022 Consolidated Insurance & Other Operating Expenses *	138.8			

\* Items may not add due to rounding



## **Invested Assets Portfolio**

- Higher interest rates led to unrealized loss of \$223 million versus \$84 million at the end of March
  - We intend to hold investments to maturity
  - Higher rates provide attractive reinvestment opportunities
- Average credit rating of A
- Portfolio remains well diversified across industries and issuers
- New money rate for 2Q 2022 of 4.2%, up from 2.7% in prior year period

#### **Key Portfolio Attributes**

(based on amortized cost (except for market value); excludes cash, period end)	Q2 2022
Fixed income / other mix	97% / 3%
Fixed income average book yield	3.25%
Average rating	А
Investment grade / BIG mix	96% /4%
Average duration	4.8 Years
Market value	\$2.6 billion
Net unrealized loss	(\$223.4) million

#### Market Value and Yield of Maturities

(\$ in millions)



